Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab

Abdelmaseih, R; Abdelmasih, R; Hasan, M; Hamza, A

Abdelmaseih, R (corresponding author), Univ Cent Florida, Coll Med, Internal Med, Ocala, FL 34474 USA.

CUREUS, 2021; 13 (6):

Abstract

Evolocumab is a recently FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) that reduces the risk of myocardial infarction,......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索